淋巴瘤新生病中骨髓多能介质干细胞免疫特征的分子变化
Nataliya A Petinati1, Aleksandra V Sadovskaya2,3, Natalia V Sats2
1National Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, 125167, Russia. loel@mail.ru.
Biochemistry. Biokhimiia
|June 16, 2024
概括
在淋巴细胞癌中,介质细胞 stromal 细胞 (MSCs) 显示出免疫功能的改变. 急性淋巴细胞白血病 (ALL) 降低了MSC度,而扩散性大B细胞淋巴瘤 (DLBCL) 增加了MSC增殖,影响了免疫调节.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 骨髓层细胞,包括多能介质层细胞 (MSCs),对于血液形成和免疫调节至关重要.
- 血液恶性瘤,如急性淋巴细胞白血病 (ALL) 和扩散性大B细胞淋巴瘤 (DLBCL),显著改变骨髓微环境.
- 了解不同淋巴细胞癌的MSC功能变化对于理解疾病发病和潜在的治疗策略至关重要.
研究的目的:
- 在ALL和DLBCL患者中研究和比较骨髓MSC的免疫功能.
- 分析ALL,DLBCL和健康对照之间的MSC生长参数,表面标记物表达,基因表达和细胞因子分泌模式的差异.
- 阐明特定类型的淋巴瘤新生病如何影响疾病发作和缓解期间的MSC行为.
主要方法:
- 从ALL患者,DLBCL (没有骨髓参与) 和年龄相匹配的健康捐赠者收集骨髓MSC.
- 对生长参数 (度,增殖),表面标记物表达和与分化和免疫功能相关的关键基因表达进行评估的MSC.
- 分析了MSC的秘密组,以确定分泌的蛋白质的差异,特别是那些参与免疫反应和干细胞维护的蛋白质.
主要成果:
- 在ALL患者中,MSC度在发病时降低,在缓解后正常化;DLBCL患者的度没有变化.
- 与对照组相比,MSC扩散在ALL中没有变化,但在DLBCL患者中显著增加 (在发病和缓解时).
- 在MSC表面标记物和基因表达特征中观察到显著差异,根据疾病类型 (ALL vs. DLBCL) 变化,与健康捐赠者相比.
- MSC的分泌体显示出对免疫调节,分化和造血干细胞维护至关重要的蛋白质的枯竭,ALL和DLBCL有不同的模式.
结论:
- 淋巴瘤新生病深刻地改变了骨髓MSCs的功能免疫状态.
- 特定类型的淋巴细胞恶性瘤 (ALL与DLBCL) 决定了MSC行为和功能的明显变化.
- 改变的MSCs有助于血液恶性瘤骨髓微环境的失调,影响免疫反应和血液形成.
相关概念视频
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
Cells of the Adaptive Immune Response
979
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
979
Bone Marrow Sampling and Transplants
324
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
324
Lineage Commitment
3.0K
Commitment is the process whereby stem cells:
3.0K
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K


